1 型糖尿病的新型和未来免疫调节疗法。
New and future immunomodulatory therapy in type 1 diabetes.
机构信息
Department of Immunobiology, Yale University, New Haven, CT 06511, USA.
出版信息
Trends Mol Med. 2012 Mar;18(3):173-81. doi: 10.1016/j.molmed.2012.01.001. Epub 2012 Feb 17.
Abstract
Type 1 diabetes is a common autoimmune disease that affects millions of people worldwide and has an incidence that is increasing at a striking rate, especially in young children. It results from the targeted self-destruction of the insulin-secreting β cells of the pancreas and requires lifelong insulin treatment. The effects of chronic hyperglycemia - the result of insulin deficiency - include secondary endorgan complications. Over the past two decades our increased understanding of the pathogenesis of this disease has led to the development of new immunomodulatory treatments. None have yet received regulatory approval, but this report highlights recent progress in this area.
摘要
1 型糖尿病是一种常见的自身免疫性疾病，影响着全球数以百万计的人群，其发病率呈惊人的上升趋势，尤其是在儿童中。它是由胰腺分泌胰岛素的β细胞被靶向性自身破坏引起的，需要终身胰岛素治疗。慢性高血糖（胰岛素缺乏的结果）的影响包括次要靶器官并发症。在过去的二十年中，我们对这种疾病发病机制的认识不断加深，导致了新的免疫调节治疗方法的发展。目前尚无一种方法获得监管部门的批准，但本报告强调了该领域的最新进展。
相似文献
1
New and future immunomodulatory therapy in type 1 diabetes.1 型糖尿病的新型和未来免疫调节疗法。
Trends Mol Med. 2012 Mar;18(3):173-81. doi: 10.1016/j.molmed.2012.01.001. Epub 2012 Feb 17.
2
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.免疫调节疗法以维持 1 型糖尿病患者的胰岛 β 细胞功能。
Nat Rev Drug Discov. 2011 Jun;10(6):439-52. doi: 10.1038/nrd3402.
3
Endoplasmic reticulum stress in beta cells and autoimmune diabetes.β细胞内质网应激与自身免疫性糖尿病
Curr Opin Immunol. 2016 Dec;43:60-66. doi: 10.1016/j.coi.2016.09.006. Epub 2016 Oct 5.
4
[Immunological intervention to preserve beta-cell function in type 1 diabetes].[1型糖尿病中保留β细胞功能的免疫干预]
Dtsch Med Wochenschr. 2010 May;135(18):915-21. doi: 10.1055/s-0030-1253678. Epub 2010 Apr 27.
5
Immunotherapy in autoimmune type 1 diabetes.自身免疫性1型糖尿病的免疫疗法。
Rev Diabet Stud. 2012 Summer-Fall;9(2-3):68-81. doi: 10.1900/RDS.2012.9.68. Epub 2012 Nov 15.
6
Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results.使用DiaPep277对1型糖尿病进行免疫调节：近期临床试验结果的简要回顾与更新
Diabetes Metab Res Rev. 2009 May;25(4):316-20. doi: 10.1002/dmrr.942.
7
Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes.维生素 D 对 1 型糖尿病胰岛自身免疫和β细胞功能的影响。
Nutrients. 2019 Sep 11;11(9):2185. doi: 10.3390/nu11092185.
8
Disease-modifying immunotherapy for the management of autoimmune diabetes.用于自身免疫性糖尿病管理的疾病修饰性免疫疗法。
Neuroimmunomodulation. 2010;17(3):173-6. doi: 10.1159/000258716. Epub 2010 Feb 4.
9
Tackling type 1 diabetes: new immune-modulating drugs attack the root cause.攻克1型糖尿病：新型免疫调节药物直击病因。
Chem Biol. 2007 Dec;14(12):1305-6. doi: 10.1016/j.chembiol.2007.12.005.
10
Immunotherapy: Building a bridge to a cure for type 1 diabetes.免疫疗法：为 1 型糖尿病的治愈搭建桥梁。
Science. 2021 Jul 30;373(6554):510-516. doi: 10.1126/science.abh1654. Epub 2021 Jul 29.
引用本文的文献
1
Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation.寻找用于1型糖尿病（T1D）和胰岛移植的有前景的免疫调节剂。
J Diabetes Res. 2024 Dec 20;2024:5151171. doi: 10.1155/jdr/5151171. eCollection 2024.
2
Cutting-edge biotechnological advancement in islet delivery using pancreatic and cellular approaches.使用胰腺和细胞方法在胰岛递送方面的前沿生物技术进展。
Future Sci OA. 2020 Nov 23;7(3):FSO660. doi: 10.2144/fsoa-2020-0105.
3
Human plasma-derived alpha -proteinase inhibitor in patients with new-onset type 1 diabetes mellitus: A randomized, placebo-controlled proof-of-concept study.人血浆来源的α-蛋白酶抑制剂在新发 1 型糖尿病患者中的应用：一项随机、安慰剂对照的概念验证研究。
Pediatr Diabetes. 2021 Mar;22(2):192-201. doi: 10.1111/pedi.13162. Epub 2020 Dec 13.
4
Chloroquine as a promising adjuvant therapy for type 1 Diabetes Mellitus.氯喹作为 1 型糖尿病有前途的辅助治疗药物。
Sci Rep. 2020 Jul 21;10(1):12098. doi: 10.1038/s41598-020-69001-2.
5
Increased β-cell proliferation before immune cell invasion prevents progression of type 1 diabetes.β细胞增殖增加可预防免疫细胞浸润导致的 1 型糖尿病进展。
Nat Metab. 2019 May;1(5):509-518. doi: 10.1038/s42255-019-0061-8. Epub 2019 May 6.
6
Development and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes.1型糖尿病中用于评估CD205介导的抗原递送疗法的临床前模型的开发与特性分析
Immunohorizons. 2019 Jun 26;3(6):236-253. doi: 10.4049/immunohorizons.1900014.
7
Current Status on Immunological Therapies for Type 1 Diabetes Mellitus.1 型糖尿病免疫治疗的现状。
Curr Diab Rep. 2019 Mar 23;19(5):22. doi: 10.1007/s11892-019-1144-3.
8
Mesenchymal Stem and Progenitor Cells in Regeneration: Tissue Specificity and Regenerative Potential.再生中的间充质干细胞和祖细胞：组织特异性与再生潜能
Stem Cells Int. 2017;2017:5173732. doi: 10.1155/2017/5173732. Epub 2017 Feb 13.
9
Effects of TRPM7/miR-34a Gene Silencing on Spatial Cognitive Function and Hippocampal Neurogenesis in Mice with Type 1 Diabetes Mellitus.TRPM7/miR-34a 基因沉默对 1 型糖尿病小鼠空间认知功能和海马神经发生的影响。
Mol Neurobiol. 2018 Feb;55(2):1568-1579. doi: 10.1007/s12035-017-0398-5. Epub 2017 Feb 9.
10
Active Subjects With Autoimmune Type 1 Diabetes Have Better Metabolic Profiles Than Sedentary Controls.患有自身免疫性1型糖尿病的活跃受试者比久坐不动的对照组具有更好的代谢状况。
Cell Transplant. 2017 Jan 24;26(1):23-32. doi: 10.3727/096368916X693022. Epub 2016 Sep 20.
本文引用的文献
1
Type 1 diabetes immunotherapy: is the glass half empty or half full?1 型糖尿病免疫疗法：是半杯水空还是半杯水满？
Sci Transl Med. 2011 Aug 10;3(95):95fs1. doi: 10.1126/scitranslmed.3002981.
2
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.胰岛抗原刺激的 T 细胞增殖反应增加可识别出 1 型糖尿病患者对抗 CD20 单克隆抗体（利妥昔单抗）治疗的临床应答者。
J Immunol. 2011 Aug 15;187(4):1998-2005. doi: 10.4049/jimmunol.1100539. Epub 2011 Jul 20.
3
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.阿巴西普治疗近期发病 1 型糖尿病患者的共刺激调节作用：一项随机、双盲、安慰剂对照试验。
Lancet. 2011 Jul 30;378(9789):412-9. doi: 10.1016/S0140-6736(11)60886-6. Epub 2011 Jun 28.
4
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.特立帕肽治疗 1 型糖尿病（Protégé 研究）：一项随机、安慰剂对照试验的 1 年结果。
Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.
5
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.基于谷氨酸脱羧酶 (GAD) 疫苗的抗原治疗在近期诊断为 1 型糖尿病患者中的应用：一项随机双盲试验。
Lancet. 2011 Jul 23;378(9788):319-27. doi: 10.1016/S0140-6736(11)60895-7. Epub 2011 Jun 27.
6
Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR).早期喂养与 1 型糖尿病风险：来自于通过遗传学手段减少糖尿病危险（TRIGR）试验的经验。
Am J Clin Nutr. 2011 Dec;94(6 Suppl):1814S-1820S. doi: 10.3945/ajcn.110.000711. Epub 2011 Jun 8.
7
Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes.维生素 D 基因的遗传变异与自身免疫性疾病 1 型糖尿病的易感性有关。
Diabetes. 2011 May;60(5):1624-31. doi: 10.2337/db10-1656. Epub 2011 Mar 25.
8
Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes.证据表明，鼻内胰岛素可诱导自身免疫性糖尿病成人对胰岛素产生免疫耐受。
Diabetes. 2011 Apr;60(4):1237-45. doi: 10.2337/db10-1360. Epub 2011 Feb 9.
9
Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.基于 CD2 表达选择性靶向人同种反应性 CD8+效应记忆 T 细胞。
Am J Transplant. 2011 Jan;11(1):22-33. doi: 10.1111/j.1600-6143.2010.03317.x. Epub 2010 Nov 10.
10
Dietary intervention in infancy and later signs of beta-cell autoimmunity.婴儿期饮食干预与后期胰岛细胞自身免疫的相关征象。
N Engl J Med. 2010 Nov 11;363(20):1900-8. doi: 10.1056/NEJMoa1004809.
Zotero 插件